Lantern Pharma (LTRN)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Oncologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-11-15. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 72/100 (HIGH), 5.9 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 10.74% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Evidence and freshness
Record counts and statuses were computed on 2026-11-17. A source date shows only when we store one; otherwise it says “not recorded”. Spot an error? Report a data error.
| PDUFA / FDA dates | 0 | No records No upcoming FDA decision date found in the company's SEC filings |
SEC 8-K filing |
| Clinical trials | 3 | Current Updated within the last 14 days |
ClinicalTrials.gov Registry queried: Nov 15, 2026 · ingested Nov 15, 2026 |
| Insider activity | 0 | Unavailable No record on file; source last refreshed Nov 17, 2026 |
SEC EDGAR Form 4 |
| Dilution risk | 1 | Derived Derived score calculated from SEC data, not a raw record |
DilutionWatch score (derived from SEC filings) source date not recorded · ingested Nov 17, 2026 |
| Short interest | 1 | Current Updated within the last 21 days |
FINRA short interest source date not recorded · ingested Nov 17, 2026 |
| Publications | 20 | Current Updated within the last 30 days |
PubMed source date not recorded · ingested Nov 16, 2026 |
How the signal grade is calculated
The score (0–100) is a weighted average of the source-backed signals we hold for a company: FDA decision date 35%, clinical trials 25%, insider buying 15%, dilution risk 8%, signal convergence 7%, short interest 3%, and 0.5–2% each for smaller signals. A signal we have no record for drops out and the others share its weight. Grades: A ≥ 80, B ≥ 65, C ≥ 50, D ≥ 35, F below 35.
What drives this company's 35.5/100 (grade D):
- Dilution risk: signal score 0.72, weight used 22%, 15.8 points
- Clinical trials: signal score 0.21, weight used 68%, 14.3 points
- Short interest: signal score 0.50, weight used 8%, 4.1 points
- Publications: signal score 1.00, weight used 1%, 1.4 points
Freshness: PDUFA dates that have passed score 0; clinical-trial records older than 90 days are ignored; dilution scores older than 7 days are withdrawn; scores are recalculated daily. Derived signals: the overall score and grade, the dilution-risk score (DilutionWatch, calculated from SEC filings) and signal convergence. The grade is not a forecast of FDA approval, a trial result or a stock move, and not investment advice.
Recent News & SEC Filings
- Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026
- Lantern Pharma secures Taiwan clearances for Phase II NSCLC study
- Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC
- Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering
- Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET
- New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global
- Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23
- New to The Street Broadcasts at 6:30 PM ET Across Bloomberg U.S., Latin America and MENA, Featuring Lantern Pharma (NASDAQ:LTRN), SafeSpace Global (OTCID:SSGC) and FreeCast (NASDAQ:CAST)
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Phase Ia Evaluation of LP-184 in Recurrent Glioblastoma: Safety, Pharmacokinetics, and Translational Optimization of CNS Exposure. — Cancer Res Commun 2026 Oct 1 PMID 42849034
- Quantitative characterization of platelet count and alanine aminotransferase dynamics to inform personalized dosing in the first-in-human LP-184 trial. — Cancer Chemother Pharmacol 2026 Aug 12 PMID 42581203
- A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors. — Invest New Drugs 2026 Oct PMID 42410111
- Chemotherapeutic induction of cytosolic single-stranded DNA accumulation sensitizes triple-negative breast cancer to immunotherapy. — J Immunother Cancer 2026 Jun 29 PMID 42373131
- Clinical outcomes of DNA-damaging agents and DNA damage response inhibitors combinations in cancer: a data-driven review. — Front Oncol 2025 PMID 40556667
20 total publications tracked — view all on BiotechSign
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Lantern Pharma.
Full LTRN Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.